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ABSTRACT
Introduction The use of patient reported outcome
measures to support routine inflammatory bowel disease
(IBD) care is not widespread and suggests that existing
questionnaires lack relevance to day-to-day decisions or
are too cumbersome to administer. We developed a
simple, generic tool for capturing disease control from
the patient’s perspective to address these barriers.
Methods Development based on literature review,
patient focus groups/interviews and a steering group,
defining a limited set of generic questions. The ‘IBD-
Control’ questionnaire comprises 13 items plus a visual
analogue scale (VAS) (0–100). Prospective validation
involved baseline completion of IBD-Control, quality of
life (QoL) questionnaire (UK-IBD-Q), EuroQol (EQ-5D),
Hospital Anxiety and Depression Score; and clinician
assessment (blinded to questionnaire; recording Harvey-
Bradshaw Index or Simple Clinical Colitis Activity Index;
Global Clinician Rating; treatment outcome).
Results 299 patients returned baseline surveys (Crohn’s
disease, n=160; ulcerative colitis, n=139) and 138
attended for repeat visits. Completion time (mean; SD):
1 min 15 s; 25 s; Internal consistency: Cronbach’s α for
all 13 items (0.85); for subgroup of eight questions
(‘IBD-Control-8’; 0.86). Strong correlation between IBD-
Control-8 and IBD-Control-VAS (r=0.81). Test-retest
reliability (2 week repeat): intra-class correlation=0.97
for IBD-Control-8 and 0.96 for IBD-Control-VAS.
Construct validity: Moderate-to-strong correlations
between IBD-Control-8 and IBD-Control-VAS versus
activity indices, UK-IBD-Q and EQ-5D (utility) with r
values 0.52–0.86. Discriminant validity (mean
instrument scores for remission, mild, moderate or
severe): p<0.001 (analysis of variance (ANOVA)).
Sensitivity to change: Effect sizes: 0.76–1.44.
Conclusions The IBD-Control is a rapid, reliable, valid
and sensitive instrument for measuring overall disease
control from the patient’s perspective. Unlike existing
patient reported outcome measures, its simplicity, ease-
of-use and generic applicability make it a candidate for
supporting routine care.
INTRODUCTION
The goal of therapy for inflammatory bowel diseases
(IBD) is to achieve and maintain disease control and
thereby optimise quality of life (QoL). Hence, assess-
ment of disease control is a core component of care
and underpins management decisions. Surprisingly,
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Significance of this study
What is already known about this subject?
▸ The routine use of patient-reported outcome
measures (PROMs) in clinical practice is
increasingly advocated as a means of
supporting patient-centred care, informing
decisions and driving service quality.
▸ A range of PROMs has been developed to
measure quality of life in inflammatory bowel
disease but none has found widespread
practical use in routine settings.
▸ Barriers to adoption of PROMs include patient
and administrator burden and lack of tangible
relevance to day-to-day decision-making or
quality assurance of services.
What are the new findings?
▸ The IBD-Control questionnaire is the first PROM
to capture disease control from the patient’s
perspective using a simple set of generic items
applicable to all patients with IBD.
▸ Summary scores from the instrument show
strong validity versus more complex quality of
life questionnaires, generic utility measures,
disease activity scores and global physician
assessment.
▸ As a patient-completed screening tool, the
IBD-Control provides a rapid and reliable means
of identifying those in a quiescent state and
the individual items and summary scores have
potential to support efficient models of disease
follow-up.
How might it impact on clinical practice in
the foreseeable future?
▸ In routine practice, IBD-Control has potential to
provide patients and healthcare teams with a
practical means of capturing simple but reliable
outcome data in a standardised and easily
interpretable form.
▸ The strong measurement properties suggest
potential for use in clinical studies, particularly
in long-term or large-scale trials, surveys or
registries where its minimal user and
administrator burden will favour serial capture
of PROM data in routine settings.
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no survey instrument has been developed for routine clinical prac-
tice with the specific aim of capturing disease control from the
patient’s perspective.
The routine use of patient reported outcome measures
(PROMs) in healthcare is gaining increasing political and profes-
sional support as a means of informing day-to-day decisions and
driving service quality.1 2 PROMs are standardised, validated
questionnaires intended for completion by patients in order to
measure their perceptions of their own functional status and
well-being. PROMs have begun to find a role in national audits
and registers and there is rapidly growing interest in their poten-
tial to inform individual care.1
No single PROM instrument has gained widespread popularity
in the UK or internationally for routine use in IBD. When formal
measurement of health status is undertaken (eg, for clinical trials)
the traditional emphasis has been on clinician-reported indices
assigning scores for selected symptoms, vital signs and laboratory
or endoscopic parameters.3–7 However, it has long been recognised
that clinician-reported indices are not entirely objective 8 and fail to
capture the impact of disease from the patient’s perspective.
The last decade has seen a wealth of qualitative research
employing focus groups, interviews, expert panels and factor
analysis to identify key issues for patients with IBD.9–17 This has
resulted in a number of multidomain PROMs being developed
as measures of disease-specific QoL, typically combining
symptom questions with more generic questions that relate to
overall well-being, energy/vitality, bodily pain and impacts of
disease on physical, social and emotional function.9–17 Only a
limited number of these instruments has found use in clinical
trials 10 16 but none has established a significant place in routine
practice. This may reflect, in part, the patient and administrator
burden inherent in using lengthy multidomain questionnaires.
Shortened forms may have more potential for routine clinical
applications 18 19 but are not used widely.
If PROMs are to find a place in routine care, instruments need
to be acceptable to patients and healthcare teams, demonstrating
added value to normal practice and with simple and
clinically-relevant interpretation. This means combining a high
level of user-friendliness (ie, short and rapidly completed tools
with low burden and easy interpretation) with strong and expli-
citly stated measurement properties to support decisions at the
level of the individual patient. The objective of this study was to
develop and validate a novel questionnaire intended to rapidly
capture disease control from the patient’s perspective
(‘IBD-Control’). Our design criteria mandated that the tool should
be short, simple and generic in content in order to maximise its
potential for routine use across the full spectrum of patients with
IBD. As there is no gold standard measure of disease control in
IBD, we used a wide array of external measures to validate the
questionnaire, including disease activity indices, generic and
disease-specific QoL questionnaires and pragmatic clinical end
points (global physician assessment and treatment outcome).
METHODS
Development phase
Design criteria: Based on the intended practical clinical applica-
tion for the IBD-Control questionnaire, we formulated a number
of guiding principles for its development. These design criteria
were used as a filter to select items generated from literature
review and the qualitative patient study. Essential attributes for
the choice of individual question items were specified as follows:
(A) Include items that capture a patient’s global self-assessment
of overall disease control; (B) Items must reflect generic areas of
concern, function or impact that are important to patients with
both main forms of IBD; (C) Items should not focus on individ-
ual gastrointestinal symptoms since their relevance and relative
importance will vary depending on disease type and extent.
Criteria for the overall design of the instrument were:
(A) Minimal user burden (ie, a rapid completion time with a
limited total number of question items and simple response cat-
egories); (B) The tool should generate overall summary scores
with clearly defined interpretation at the individual patient
level; and (C) The development and validation process should
provide evidence for its acceptability, reliability, validity and
responsiveness based on modern psychometric standards.20–22
The project was guided by a steering group of medical and
nursing professionals with expertise in the management of IBD.
Literature review of existing PROMS used in IBD: A detailed
review of the English-language literature was undertaken using the
PubMed electronic database supplemented with manual searching
of bibliographies and conference proceedings within relevant jour-
nals. We used combinations of the search terms ‘inflammatory
bowel disease’, ‘ulcerative colitis’, ‘Crohn’s disease’, ‘question-
naire’, ‘validation’, ‘quality of life’, ‘patient-reported outcome’ and
‘control’. We excluded clinician-reported measures (ie, disease
activity indices) and those developed specifically for paediatric
patients. Self-administered PROMS reported for adult patients
with patients with IBD where categorised as either generic (instru-
ments developed originally for general use across different dis-
eases) or disease-specific (tools developed specifically for patients
with IBD). From the literature review we generated a list of core
domains (figure 1) to serve as a framework for analysing outputs
of the qualitative work with patients.
Qualitative study: We undertook two focus groups (six
patients), one for each condition (ulcerative colitis (UC) or
Crohn’s disease (CD)) plus 13 one-to-one interviews with
informed consent. A semistructured approach was taken to
encourage patients to talk about the general concept of ‘control’
of IBD and the things they associated with ‘good control’ or
‘poor control’. Verbatim contributions were recorded and sum-
marised as field notes by the lead interviewer (CO). These items
or themes were grouped and mapped onto a framework based
on the review of existing IBD questionnaires. At the end of each
session, the patients were shown a selection of questionnaires
and asked to contribute ideas or preferences about question
format, layout, response categories, item number and comple-
tion time. ‘Saturation’ was reached when patient interviews
ceased to add new items or themes to the existing framework.
Selection of items: First, we selected a set of generic questions to
represent each of the core domains (figure 1), identifying where
possible individual question items that have broad, general cover-
age rather than specific wording to conform to our design criteria.
For example, the item selected for social impact would ask about
missing ‘planned activities’ (rather than a more specific question
about missing ‘work’, ‘study’ or ‘a social event’). To qualify for
potential inclusion in the IBD-Control, each item needed to be
identified as relevant to the construct of disease control in the
patient contributions and validated in piloting.
Piloting and modification: To test for acceptability, lack of
ambiguity and content validity we pretested the draft instrument
in a pilot group of 30 patients who were asked to complete the
IBD-Control and provide verbal or written feedback or annota-
tions regarding content and format. This resulted in changes to
item wording or layout.
Prospective validation phase (psychometric testing)
The prospective validation study recruited patients at the investi-
gating centre, a university hospital serving a population of
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approximately 330 000 people with an established secondary
care IBD service providing outpatient and inpatient medical and
surgical care.23 Patients were recruited during routine visits to
the outpatient clinics prior to consultation with the doctor or
specialist nurse, during other treatment-related visits (eg,
azathioprine monitoring clinic or infusion visit for biologics) or
at the time of admission for inpatient care. Inclusion criteria
specified a confirmed diagnosis of IBD on the basis of clinical,
endoscopic, radiological and/or histological criteria with disease
duration of at least 6 months. Exclusion criteria specified
non-English speaking subjects, cognitive impairment or serious
active psychiatric disease.
After informed consent, the patients completed the
IBD-Control questionnaire and were then asked to complete a
questionnaire pack comprising a disease-specific QoL question-
naire (the UK-IBD-QoL),16 17 a generic health status instrument
(EuroQol, EQ-5D-3L),24 and the Hospital Anxiety and
Depression Scale.25 The research team undertook a simultaneous
assessment of current disease activity, using the Harvey-Bradshaw
Index (HBI) for CD 5 and the Simple Clinical Colitis Activity
Index (SCCAI) for UC.6 The research team and clinicians were
blinded to the results of patient-completed questionnaires.
Where the study visit was taking place at a scheduled clinical
review (eg, outpatient attendance), the treating clinician or spe-
cialist nurse was asked to complete a questionnaire at the end of
the consultation to indicate the current state of IBD (Global
Physician Assessment) using a categorical scale (remission, mild,
moderate or severe), blinded to patient surveys. All treatment
decisions were recorded, capturing whether new therapies were
started, existing drug doses changed, therapies discontinued or
surgery recommended. The research team reviewed the hospital
case records and clinical information systems to extract back-
ground clinical information regarding diagnosis, duration of
disease, previous hospitalisation and surgery, disease extent,
presence of stoma or perianal fistulae, major comorbid illness
and current therapy for their IBD.
Assessment of psychometric (measurement) properties of
IBD-Control
Internal consistency was assessed for categorical questions and
any subscales derived from them using Cronbach’s α.26 In
addition, we used Spearman’s correlation to study the associ-
ation between individual categorical questions and the rating
from the instrument’s visual analogue scale (IBD-Control-VAS).
Reproducibility was assessed under two sets of conditions
using serial observations and the Intraclass Correlation
Coefficient. First, a group of 20 patients underwent a repeat
assessment at 2 weeks from baseline, completing the
IBD-Control and UK-IBD-QoL on both occasions (test-retest
group). In this group, we defined a stable health state based on
the patient’s response to the IBD-Control transition question
item (Q2, response=‘No change’) plus ≤10-point change on the
UK-IBD-Q total score. Second, we compared IBD-Control
scores obtained from a group of patients who completed assess-
ments at baseline and then at a subsequent routinely scheduled
visit (routine care group). In this group, we defined a stable
state on the basis of there being no change in the physician
global assessment between visits.
Construct validity was assessed by comparing the scores
derived from the questionnaire with several independent exter-
nal measures of patient health state. These measures included
generic QoL (EQ-5D utility index and EQ-5D visual analogue
score), disease specific QoL (UK-IBD-QoL), physician global
assessment and clinical disease activity indices. Bivariate correla-
tions were expressed as Spearman’s correlation coefficients and
between-group mean scores were compared by t test or analysis
of variance (ANOVA). Multiple variable linear regression was
used to explore the relative strength and independence of indi-
vidual question items as predictors of the various external mea-
sures of health state and to select items to include in subscores.
Responsiveness was assessed in those patients who completed
baseline and follow-up assessments and experienced a change in
their health state. There is no true external gold standard to
define a change in disease control and so we performed respon-
siveness analyses using two alternative external criteria to define
a change in health state between visits. First, we defined
improvement or deterioration on the basis of self-reported
UK-IBD-QoL total score, with a change of >10 points taken as
a cut-off. As an alternative, we used the physician global rating
to identify a change in clinical state (any change from baseline
category, eg, mild to moderate). A range of responsiveness statis-
tics were calculated including correlations in change scores,
Figure 1 Flow chart summarising
development and validation of
IBD-Control. IBD, inflammatory bowel
disease.
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effect size, standardised response mean (SRM) and modified
SRM (MSRM).
Definition and evaluation of cut-off values for detecting the
‘quiescent’ state: A key potential application for IBD-Control
was to serve as a screening test to rapidly and reliably identify
patients with optimal self-reported disease control. Such patients
are suitable for alternative forms of chronic disease follow-up
(eg, self-care, telephone or virtual clinics) rather than trad-
itional, costly and inconvenient office or clinic attendance. We
defined a state of ‘quiescent’ disease using a combination of
parameters, as follows:
1. Disease-specific measures consistent with clinical remission
as defined by disease activity indices within reported remis-
sion ranges (SCCAI<4; HBI<5), UK-IBD-QoL total score
≥90 points and Physician Global Assessment rated as ‘remis-
sion’. To allow for missing or incomplete data, patients were
required to have sufficient data to satisfy any two of the
criteria.
2. Not currently receiving oral corticosteroid therapy, a course
of antibiotics, therapeutic (polymeric) diet, induction with
biologics or awaiting surgical treatment.
3. IBD-Control transition question (Q2) indicates condition
was unchanged or improved in the last 2 weeks (ie, exclud-
ing patients who responded that bowel symptoms were
‘worse’).
4. No escalation of therapy occurred as a consequence of the
clinical consultation.
Individuals satisfying all four of the above criteria would be
regarded as well-controlled. Patients who did not meet these cri-
teria where designated as ‘not quiescent’. We used receiver-
operating characteristics analysis to assess the performance of
the IBD-Control as a tool for identifying this subgroup of quies-
cent patients. Given the intended clinical application, we
defined optimum cut-off scores with an emphasis on achieving
high specificity (≥85%) to minimise the risk of false positives
(identifying a non-quiescent patient as quiescent). The cut-off




Literature review: A PubMed search identified 7244 references
with a combination of search terms: [‘Patient reported outcome
measure’ OR ‘PROM’ OR ‘quality of life’ OR ‘questionnaire’ OR
‘outcome measure’] AND [‘Inflammatory bowel disease’ OR
‘ulcerative colitis’ OR ‘Crohn’s disease’ OR ‘colitis’ OR ‘IBD’].
Of these, 682 articles included the additional terms: [‘develop-
ment’ or ‘validation’ OR ‘psychometric’]. We identified 71 rele-
vant articles relating either to IBD-specific questionnaires (23
instruments for adults including variants or short forms; 4 for
paediatrics were excluded) or to the validation of existing generic
PROMS in patients with IBD (3 instruments). Of the disease-
specific PROMS for adults with IBD, only the original McMaster
IBD-Q (32 items) 10 and a similar instrument developed in the
UK 17 were found to have undergone detailed psychometric
evaluation in accordance with modern guidelines 20 21 and subse-
quent use as outcome measures in clinical trials. Hence, we chose
the UK IBD-Q as our measure of QoL in the validation study. Of
the generic instruments, the EuroQoL EQ-5D 24 had the most
publications and so was our choice of utility measure. No instru-
ment was identified that measured IBD disease control from the
patient perspective but we reviewed questionnaires for other
chronic diseases.
Focus groups and one-to-one interviews: Saturation was
reached after completing two focus groups and 13 one-to-one
interviews. Consistently, the idea of disease control was
expressed by contributors as their overall sense that
disease-related symptoms were minimised or absent (ie, a global
sense of control). As expected, the control of a wide variety of
specific gastrointestinal symptoms was identified as important by
individual patients but these did not meet our criteria for
generic item selection. However, a common theme across all
participants was the idea that good control implied that their
particular array of bowel symptoms was minimised and not
impacting on day-to-day physical functioning (overall energy
and vitality; and sleep), social functioning (daily activities, work
and recreational) or emotional functioning (feelings of anxiety
or depression). In addition, the control of symptoms of discom-
fort or pain was a distinct factor. Loss of disease control was
expressed as either a worsening of overall bowel symptoms or
the development of an unfamiliar new symptom.
Control of IBD was linked also with ideas about the perceived
effectiveness or acceptability of current treatments. This is not a
core theme that appears in the established model for QoL in
IBD.9–19 Good control would imply feelings that treatment was
‘right’ or ‘was working’ whereas poor control would invoke the
sense that treatment was ineffective. For some patients, the
ability to control the condition themselves (ie, by making adjust-
ments to medication according to symptoms) was seen as part
of the concept of disease control. Additional treatment-related
themes included perceived difficulties with using certain drugs
or side effect. Good control would imply a lack of such treat-
ment concerns.
Description and specification of the IBD-Control instrument
The IBD-Control instrument is shown in online supplementary
appendix 1. The paper version comprises a single-sided A4
document that includes five sections numbered 1 through 5.
The first four sections contain a series of 13 categorical ques-
tions, each of which has three response options. Of the categor-
ical questions, 12 items have response options of ‘Yes’, ‘No’ or
‘Not sure’ and the remaining question is a transition question
for overall bowel symptoms with options of ‘Better’, ‘No
change’ or ‘Worse’. The fifth section contains the horizontal
VAS, anchored between zero (worst possible control) and 100
(best possible control). The time horizon for disease control
assessment is the ‘past 2 weeks’.
Scoring: Each response to the 13 individual items is scored as
follows: zero points for least favourable reply; one point for
intermediate or indeterminate reply; two points for most favour-
able reply. The IBD-Control-8 subscore is calculated by
summing scores for Q1a, Q1b, Q3a, Q3b, Q3c, Q3d, Q3e and
Q3f resulting in a range of 0–16 (0=worst control). The ration-
ale for selecting this subgroup of eight questions is explained
later in the results section. The IBD-Control-VAS scores are in
the range 0–100 (0=worst control).
Validation phase
Patient sample
The characteristics of the patient sample at baseline are sum-
marised in table 1. There were 299 patients who completed the
baseline assessment, of whom 160 (53.5%) had a diagnosis of CD
and 139 (46.5%) were suffering from UC. The spectrum of
disease severity was very similar between the two forms of IBD
(CD vs UC), with no significant difference in mean scores for
generic QoL (EQ-5D utility or VAS), disease-specific QoL
(UK-IBD-QoL total score) or proportion of patients in remission
Bodger K, et al. Gut 2014;63:1092–1102. doi:10.1136/gutjnl-2013-305600 1095
Inflammatory bowel disease
(physician global assessment). Of the baseline cohort, 138 patients
were recruited to undertake a repeat assessment at a scheduled
follow-up visit (returning patients), summarised in table 2. Patients
were recruited between March 2011 and June 2012.
Acceptability and feasibility
Completion time was measured in a sample of 10 patients (aged
between 25 years and 64 years), with a mean completion time
for the IBD-Control of 1 min and 15 s (SD: 25 s). The range
was between 42 s and 2 min 1 s. Completion rates for the 13
individual questions ranged between 93.3% (Q2) and 99%
(Q3a and Q3d). Of the 299 patients who completed the
IBD-Control at baseline visit, 259 (86.6%) provided responses
to all 13 question items and 272 (91%) completed the VAS
question. We prespecified that any question returning the same
response from 80% or more of the patients would be consid-
ered for exclusion from the questionnaire. Such questions are
unlikely to be sensitive to different levels of severity. However,
none of the question items yielded the same response from 80%
or more of the patients.
Internal consistency
Scored responses to each of the 13 individual questions showed
significant positive correlations with the IBD-Control-VAS score,
with Spearman’s ρ values ranging from 0.24 to 0.70 (table 3).
These findings suggest that the individual items within the ques-
tionnaire are measuring aspects of the same construct (‘disease
control’) and that there is internal consistency within the ques-
tionnaire. A linear regression model retaining eight of the
Table 2 Characteristics of 138 patients with inflammatory bowel






Number of cases 138 82 56
Age, years 41 [15] 38 [13] 45 [16]
Gender
Male 65 (47.1%) 36 (43.9%) 29 (51.8%)
Female 73 (52.9%) 46 (56.1%) 27 (48.2%)
Disease duration, years 8 [9] 9 [8] 8 [9]
Previous surgery
Yes 45 (32.6%) 43 (52.4%) 2 (3.6%)
No 93 (67.4%) 39 (47.6%) 54 (96.4%)
Perianal disease (fistula)
Yes 20 (14.5%) 20 (24.4%) 0 (0.0%)
No 118 (85.5%) 62 (75.6%) 56 (100.0%)
Stoma present
Yes 5 (3.6%) 4 (4.9%) 1 (1.8%)
No 133 (96.4%) 78 (95.1%) 55 (98.2%)
Medication
Topical 5-ASA 11 (8.0%) 0 (0.0%) 11 (19.6%)
Topical steroid 5 (3.6%) 0 (0.0%) 5 (8.9%)
Oral 5-ASA 82 (59.4%) 34 (41.5%) 48 (85.7%)
Oral corticosteroid 16 (11.6%) 6 (7.3%) 10 (17.9%)
Standard
immunosuppressants
61 (44.2%) 44 (53.7%) 17 (30.4%)
Biological agent 29 (21.0%) 24 (29.3%) 5 (8.9%)
Dietary therapy
(polymeric diet)
5 (3.6%) 5 (6.1%) 0 (0.0%)
Disease activity indices
Harvey-Bradshaw index n/a 5 [5] n/a
Simple Clinical Colitis
Activity index
n/a n/a 5 [4]
Quality of life questionnaires
EQ-5D utility score 0.61 [0.34] 0.60 [0.35] 0.62 [0.33]
EQ-5D visual analogue
scale
61 [23] 63 [22] 56 [25]
UK-IBD-Q 83 [19] 84 [18] 82 [22]
Physician global assessment
Remission 49 (44.1%) 27 (44.3%) 22 (44.0%)
Mild 38 (34.2%) 26 (42.6%) 12 (24.0%)
Moderate 18 (16.2%) 6 (9.8%) 12 (24.0%)
Severe 6 (5.4%) 2 (3.3%) 4 (8.0%)
Continuous variables expressed as mean [SD] and categorical variables as number
(%) where appropriate).
Table 1 Characteristics of 299 patients with inflammatory bowel






Number of cases 299 160 139
Age, years 43 [16] 41 [15] 46 [16]
Gender
Male 130 (43.5%) 68 (57.5%) 77 (55.4%)
Female 169 (56.5%) 92 (42.5%) 62 (44.6%)
Disease duration, years 10 [10] 10 [10] 9 [10]
Previous surgery
Yes 83 (27.8%) 76 (47.5%) 7 (5.0%)
No 216 (72.2%) 84 (52.5%) 132 (95.0%)
Perianal disease (fistula)
Yes 27 (9.0%) 27 (16.9%) 0 (0.0%)




Yes 10 (3.3%) 8 (5.0%) 2 (1.4%)




Topical 5-ASA 36 (12.0%) 2 (1.3%) 34 (24.5%)
Topical steroid 9 (3.0%) 2 (1.3%) 7 (5.0%)
Oral 5-ASA 177 (59.2%) 68 (42.5%) 109 (78.4%)
Oral corticosteroid 26 (8.9%) 10 (6.3%) 16 (11.5%)
Standard
immunosuppressants
104 (34.8%) 71 (44.4%) 33 (23.7%)
Biological agent 38 (12.7%) 30 (18.8%) 8 (5.8%)
Dietary therapy
(polymeric diet)




n/a 5 [5] n/a
Simple Clinical Colitis
Activity index
n/a n/a 4 [3]
Quality of life questionnaires
EQ-5D utility score 0.68 [0.30] 0.65 [0.30] 0.70 [0.29]
EQ-5D visual
analogue scale
65 [23] 65 [22] 65 [24]
UK-IBD-Q 86 [20] 85 [18] 88 [21]
Physician global assessment
Remission 161 (61.9%) 80 (60.6%) 81 (63.3%)
Mild 58 (22.3%) 37 (28.0%) 21 (16.4%)
Moderate 30 (11.5%) 11 (8.3%) 19 (14.8%)
Severe 11 (4.2%) 4 (3.0%) 7 (5.5%)
Continuous variables expressed as mean [SD] and categorical variables as number
(%) where appropriate.
1096 Bodger K, et al. Gut 2014;63:1092–1102. doi:10.1136/gutjnl-2013-305600
Inflammatory bowel disease
question items (IBD-Control-8) accounted for 70% of the vari-
ance in the IBD-Control-VAS score (R-Square 0.704). Bivariate
correlation coefficients for each of the eight items within the
IBD-Control-8 subscore ranged from 0.39 to 0.70.
We assessed degree of agreement between the 13 categorical
question items by Cronbach’s α statistic.26 The higher the α
value, the higher the internal consistency between the individual
questions. A score above 0.70 is regarded as desirable but values
in excess of 0.90 are suggestive of excessive overlap or redun-
dancy between individual items. In the present study,
Cronbach’s α was 0.85 overall for all 13 question items and
0.86 for the subscore of eight questions (IBD-Control-8). This
provides further evidence for internal consistency for the
‘disease control’ construct.
The IBD-Control-8 subscore and the IBD-Control-VAS score
are intended to represent a summary measure of the same con-
struct (ie, an overall rating of disease control from the patient’s
perspective). Hence, the two summary scores should show a
strong positive correlation with each other. This was confirmed
for patients with IBD overall (r=0.811; p<0.001), and for CD
(r=0.78; p<0.001) and UC (r=0.83; p<0.001) separately.
Reliability
This was tested under two sets of conditions. First, we evaluated
reliability in a test-retest group of patients who completed eva-
luations 2 weeks apart. Of the 20 subjects, 13 reported no
change in their disease control over the past 2 weeks
(IBD-Control transition question, Q2) and had stable
UK-IBD-QoL scores (±10-points from baseline). There was no
significant difference in mean IBD-Control-8 or
IBD-Control-VAS scores between visits and the intraclass correl-
ation coefficient was 0.97 for the IBD-Control-8 subscore and
0.96 for IBD-Control-VAS (table 4A; p<0.01).
Second, reliability was assessed in 32 patients who completed
questionnaires at consecutive clinical visits and were categorised
as having no change in their physician global assessment
between the two visits. The mean interval between the two
visits was 131 days. Again, there was no significant difference in
mean summary scores on the IBD-Control questionnaire
between visits. For these patients, intraclass correlation
coefficient was 0.87 for the IBD-Control-8 subscore and 0.81
for IBD-Control-VAS (table 4A; p<0.01).
Construct validity
There is no true gold standard for measuring disease control
from the patient’s perspective. However, it is possible to test a
number of hypotheses concerning the logical relationships that
should exist between the item scores or summary scores
obtained with the IBD-Control instrument and a range of other
external criteria, measures or patient characteristics.
Validity of individual question items: Good disease control
would be expected to be associated with better QoL. Consistent
with this, each individual question item within the IBD-Control
demonstrated a significant positive correlation with the total score
for the UK-IBD-QoL (table 3). Hence, ‘positive’ responses to ques-
tions within the IBD-Control are correlated with better overall
Table 3 Correlation between individual question items within the IBD-Control instrument and visual analogue scale for disease control
(IBD-Control-VAS) and disease-specific quality of life total score measured using the UK-IBD-QoL questionnaire
Item Question IBD-Control-VAS UK-IBD-QoL
Q1a … your IBD has been well controlled in the past 2 weeks* 0.70 0.63
Q1b … your current treatment is useful in controlling your IBD* 0.39 0.38
Q2 … have your bowel symptoms been getting better, getting worse or not changed 0.36 0.24
Q3a … miss any planned activities because of IBD* 0.63 0.67
Q3b … wake up at night because of symptoms of IBD* 0.61 0.67
Q3c … suffer from significant pain or discomfort* 0.64 0.66
Q3d … often feel lacking in energy (fatigued)* 0.51 0.63
Q3e … feel anxious or depressed because of your IBD* 0.58 0.70
Q3f ... think you need a change to your treatment* 0.60 0.50
Q4a … would you like to discuss alternative types of drug 0.42 0.26
Q4b … would you like to discuss ways to adjust your own treatment 0.33 0.31
Q4c … would you like to discuss side effects or difficulties with your medicines 0.24 0.29
Q4d … would you like to discuss new symptoms that have developed 0.30 0.29
Item responses were scored as 0 (worst option), 1 (intermediate, eg, ‘Not sure’) or 2 (best option), so a higher score should indicate better disease control. Correlation coefficients are
expressed as Spearman’s ρ values (p<0.01 in all cases).
*Question items included in the IBD-Control-8 subscore.
IBD, inflammatory bowel disease; QoL, quality of life.











(A) Patients returning at 2 weeks (test-retest group)*
IBD-Control-8
subscore (0–16)
−0.45 1.81 0.97 (0.90 to 0.99)
IBD-Control-VAS
(0–100)
+2.25 9.79 0.96 (0.88 to 0.99)
(B) Patients returning for a scheduled clinic visit (routine care group)†
IBD-Control-8
subscore (0–16)
0.00 3.72 0.87 (0.71 to 0.94)
IBD-Control-VAS
(0–100)
−0.56 23.00 0.81 (0.58 to 0.91)
*Data for 13 patients responding ‘not changed’ to the IBD-Control transition question
(‘Over the past 2 weeks have your bowel symptoms been getting worse, getting
better or not changed’) and with stable UK-IBD-Qol total scores (<10-point change
between two visits).
†Data for 32 patients with a stable (unchanged) physician global assessment rating
between two visits (mean interval between visits 131 days).
Two-way fixed effects model for consistency, p<0.001.
IBD, inflammatory bowel disease; QoL, quality of life; VAS, visual analogue scale.
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disease-specific QoL. The correlation coefficients for each of the
IBD-Control-8 subscore items and total UK-IBD-QoL score
ranged from 0.38 to 0.70. These findings suggest the individual
items within the instrument are valid.
We used a single question item to capture feelings of anxiety
or depression (‘… felt anxious or depressed because of your
IBD’). Responses to this question (No, Not Sure, Yes) showed
moderate-to-strong correlation with the summary scores for the
multi-item Hospital Anxiety and Depression Scale questionnaire
25for anxiety and depression subscores (r=0.57 and r=0.62,
respectively, p<0.001).
Validity of IBD-Control summary scores: The summary scores
generated by the disease control measure are predicted to correl-
ate positively with disease-specific (UK-IBD-QoL) and generic
(EQ-5D utility and VAS) QoL scores. Consistent with this, we
found moderate-to-strong positive correlations between the
IBD-Control summary scores (IBD-Control-8 and
IBD-Control-VAS) and each of the QoL scales (table 5 and
figure 2). A linear regression model containing the eight items
from the IBD-Control-8 subscore accounted for 75% of the
variance in UK-IBD-QoL total score (R Square 0.747).
Conversely, negative correlations would be expected to exist
between IBD-Control summary scores and traditional clinical
measures of disease activity or severity. In the present study, we
obtained clinician-reported outcomes in the form of traditional
symptom-based activity indices (HBI or SCCAI) and also as a
global physician rating of current disease activity. We found
highly significant moderate-to-strong correlations between the
IBD-Control scores and the disease severity measures in the
expected direction (ie, negative coefficients) (table 5).
These associations provide strong evidence to support the con-
struct validity of the IBD-Control instrument. In addition, a valid
measure of disease control would be expected to differentiate
between mutually exclusive groups of patients categorised using
an accepted external clinical criterion. Hence, mean scores for
disease control would be expected to be significantly different
between patients ‘in remission’ and those with ‘active disease’.
Comparison of mean IBD-Control-8 and IBD-Control-VAS
scores across the four physician global assessment categories
(remission, mild, moderate or severe) confirmed good discrimin-
ant validity across the spectrum of disease (figure 3).
Multiple linear regression models examined whether add-
itional patient factors (age, gender, disease type, previous
surgery) were independently associated with IBD-Control scores
after taking account of current disease severity. All models con-
firmed the strong association between IBD-Control summary
scores and disease activity indices, generic and disease-specific
QoL and global assessment. However, no consistent independ-
ent associations were observed for the other predictor variables.
Mapping of IBD-Control-8 to EQ-5D utilities: Ease of use
makes the IBD-Control a candidate outcome measure for large
scale observational clinical studies, trials, surveys or registries.
Hence, the ability to convert IBD-Control summary scores to an
estimate of utility could support health economic evaluations.
Figure 4 illustrates the association between IBD-Control-8 sub-
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Figure 2 Validity of IBD-Control summary scores in relation to
UK-IBD-QoL Questionnaire. IBD, inflammatory bowel disease;
QoL, quality of life.
Table 5 Construct validity: Correlations between the IBD-Control
summary scores and external measures of health status in patients
with inflammatory bowel disease (IBD) at baseline assessment
External measure
IBD-Control-8 IBD-Control-VAS
All CD UC All CD UC
UK-IBD-QoL score 0.86 0.81 0.90 0.76 0.65 0.85
EQ-5D utility score 0.70 0.68 0.67 0.52 0.50 0.58
EQ-5D VAS 0.68 0.65 0.71 0.70 0.69 0.71
Physician global
assessment
−0.58 −0.45 −0.67 −0.58 −0.47 −0.65
Harvey-Bradshaw Index n/a −0.68 n/a n/a −0.60 n/a
Simple Clinical Colitis
Activity Index
n/a n/a −0.72 n/a n/a −0.75
Correlation expressed as Spearman’s ρ values (p<0.01 in all cases).
CD, Crohn’s disease; QoL, quality of life; UC, ulcerative colitis, VAS, visual analogue
scale.
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Items not included in the IBD-Control-8 subscore: Five ques-
tions were excluded from the IBD-Control-8 summary subscore.
The transition question (Q2) was excluded since this asks about
change in status over 2 weeks rather than measuring current
health status. The remaining questions (grouped together as
items Q4a to 4d in the final questionnaire) had significant but
weaker correlations with IBD-Control-VAS and/or UK-IBD-QoL
and did not add significantly to performance of linear regression
models predicting these measures. However, the development
of new symptoms (Q4d) was regarded as an important
‘stand-alone’ item to retain in the IBD-Control instrument since
a new symptom should serve as an automatic trigger for trad-
itional clinical evaluation.
The three remaining questions (Q4a to 4c) are related to
treatment concerns. These items were found to be predictive of
the clinical outcome of the consultation in terms of likelihood
of treatment escalation (note that clinicians were blinded to
questionnaire responses). Of 67 patients reporting no treatment
concerns on the three items, only 5 (7.5%) had their treatment
escalated, whereas 59 of 192 (30.7%) patients with indetermin-
ate or positive responses to at least one of the three questions
had treatment escalated (p<0.001, χ2 test; OR: 4.1 (95% CI
1.7 to 9.8)).
Responsiveness
A vital measurement property for any PROM is that the instru-
ment is sensitive to gains or losses in the measurement concept
of interest. We evaluated the responsiveness of the instrument
by comparing serial data collected in the patients who returned
for a second visit.
Change scores: A crude method for assessing responsiveness is
to calculate ‘change scores’ for the instrument (ie, subtract score
at visit 1 from the score at visit 2) and to examine the correl-
ation between this value and a change score derived from
another relevant clinical measure. For change scores in
IBD-Control-8 subscore and IBD-Control-VAS, there were sig-
nificant correlations with change scores for each of the key
external outcome measures (r values ranging from 0.25 to
0.78). The strongest correlation for change in IBD-Control
scores were versus the change in UK-IBD-QoL total score
(IBD-Control-8, r=0.72; IBD-Control-VAS, r=0.55; p<0.001)
and the weakest for HBI (IBD-Control-8, r=−0.25;
IBD-Control-VAS, r=−0.32; p<0.001).
Responsiveness statistics: Several methods have been proposed
to provide more robust quantitative expressions of the magni-
tude and meaning of changes in instrument scores. Effect size
(ES) is calculated as the size of the change in scores (ie, the dif-
ference between mean scores at the baseline and repeat assess-
ments) divided by the SD of baseline scores. Benchmarks for
assessing the relative size of change have been proposed
whereby an ES of 0.2 is considered small, 0.5 as medium and
≥0.8 as large. The IBD-Control-8 and IBD-Control-VAS showed
moderate-to-strong ES with values ≥0.76 (table 6) indicating
good responsiveness.
The SRM differs from ES in that the denominator is the SD
of change scores (rather than of baseline scores). This takes
account of variability in change per se rather than variability in
absolute baseline scores. Responsiveness of the IBD-Control
summary scores measured by SRM was strong (table 6).
Finally, in the modified SRM (MSRM) the numerator remains
the mean change in absolute scores for the group but for this
statistic the denominator is the SD of change scores taken specif-
ically from individuals who are identified by other means as
clinically stable. In the present study, this was taken from a sub-
group of patients who showed no change in physician global
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Figure 4 Validity of IBD-Control-8 subscore in relation to EuroQol
(EQ-5D) utility index. IBD, inflammatory bowel disease; QoL, quality of
life.
Figure 3 Validity of IBD-Control summary scores in relation to
physician global assessment.
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QoL score (UK-IBD-Q total score changed by no more than
10 points between visits). The IBD-Control-8 and the
IBD-Control-VAS scores have MSRM values ≥0.86 (table 6).
Sensitivity and specificity of IBD-control in identifying ‘quiescent’
patients
Of 217 patients at baseline who had formal clinical assessment
and all relevant data, 80 individuals could be categorised as quies-
cent at the time of their routinely scheduled clinic visit. None
required treatment escalation (including induction with biologics
or referral for surgery). Receiver-operating characteristics analysis
for IBD-Control-8 subscore and IBD-Control-VAS indicated
strong performance could be achieved with either measure as a
test to identify quiescent patients from the remaining cases
(figure 5). For IBD-Control-8, a cut-off of ≥13 points identified
patients with quiescent IBD with 67.5% sensitivity and 90.6%
specificity, whereas for IBD-Control-VAS a cut-off of ≥85 points
achieved 64.3% sensitivity and 90% specificity. These cut-off
scores would mean that only 1 in 10 patients failing to meet our
stringent clinical criteria for quiescent IBD would be falsely cate-
gorised as quiescent but none of these ‘false positives’ required any
treatment change at the time of consultation and all were consid-
ered to be either in remission or only mildly active by the attending
clinician. These data confirm the potential clinical application of
IBD-Control as a rapid triage tool to categorise low-risk (quies-
cent) patients suitable for alternative forms of follow-up.
DISCUSSION
The IBD-Control questionnaire is a novel PROM designed to
provide a rapid, user-friendly assessment of disease control from
a patient’s perspective. It was developed with patient involve-
ment in defining the measurement construct (ie, what is ‘disease
control’?) and in generating patient-centred items. Key require-
ments were that IBD-Control should be applicable to routine
clinical care and that it would contain items relevant to both
main forms of IBD. This resulted in the generation of a short
and deliberately generic set of questions.
As expected, there was considerable consensus and overlap
between items or domains identified by patient discussions of
Table 6 Responsiveness statistics for the IBD-Control summary scores in subjects who improved or deteriorated. Data for stable patients (no
change) are included for reference
Criteria for change in state n Mean difference (SD) Effect size* Standardised response mean† Modified standardised response mean‡
(A) IBD-Control-8 sub-score
UK-IBD-QoL
Improved by >10 points 19 +5.50 (4.69) 1.44 1.17 2.72
No change (±10 points) 63 +0.13 (2.02) 0.02 0.06 0.06
Deteriorated by >10 points 26 −4.92 (3.88) 0.99 1.27 2.44
Physician global assessment
Improved by ≥1 point 27 +4.52 (5.56) 1.08 0.81 1.22
No change 32 0.00 (3.72) 0.00 0.00 0.00
Deteriorated by ≥1 point 27 −3.32 (4.81) 0.76 0.69 0.89
(B) IBD-Control-VAS
UK-IBD-QoL
Improved by >10 points 19 +28.21 (31.33) 1.09 0.90 1.84
No change (±10 points) 63 +0.84 (15.34) 0.03 0.05 0.05
Deteriorated by >10 points 26 −26.85 (28.20) 0.90 0.95 1.75
Physician global assessment
Improved by ≥1 point 27 +29.55 (31.78) 1.14 0.93 1.28
No change 32 −0.56 (23.00) 0.02 0.02 0.02
Deteriorated by ≥1 point 27 −19.71 (30.53) 0.76 0.65 0.86
*Effect size (ES)=Mean difference divided by the SD of the baseline absolute scores for the group.
†Standardised response mean (SRM)=Mean difference divided by SD of the difference for the group.
‡Modified SRM (MSRM)=Mean difference for the group divided by SD of the difference for unchanged patients.


















Figure 5 Performance of IBD-Control as a screening test to identify
‘quiescent’ patients: Receiver operating characteristic (ROC) curves for
IBD-Control-8 subscore (solid line; area under curve: 0.90; p<0.001)
and IBD-Control-VAS (broken line; area under curve: 0.86; p<0.001).
For IBD-Control-8, a cut-off of ≥13 points identified patients with
quiescent IBD with 67.5% sensitivity and 90.6% specificity, whereas
for IBD-Control-VAS a cut-off of ≥85 points achieved 64.3% sensitivity
and 90% specificity. The quiescent state was defined using strict
composite criteria (see text). IBD, inflammatory bowel disease.
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disease control and the themes reported in the extensive litera-
ture on QoL in IBD.9–19 28–30 Hence, good control implies the
absence of disease impacts on energy/vitality, ability to perform
daily activities, sleep, mood and freedom from pain or discom-
fort. Question items on these topics feature prominently in
short forms of existing disease-specific QoL questionnaires
and/or in the generic instruments that have been applied to IBD.
In addition, our qualitative study identified a discrete domain of
‘treatment concerns’, encompassing perceptions of effectiveness
of treatment, satisfaction with choice of therapy, ability to adjust
own treatment and concern about side effects and we incorpo-
rated these items into the IBD-Control.
This study shows that IBD-Control is acceptable to patients
based on its rapid completion time and high completion rates.
Acceptability is a vital characteristic for any PROM if the
intended application is to support routine care—a property that
may be lacking with the current multi-item, multidomain QoL
measures. Despite its simplicity, the IBD-Control exhibits strong
measurement properties.
Strengths of the present study include our emphasis on
patient involvement in item generation and questionnaire design
to complement literature review and clinical opinion.
Furthermore, we adopted a comprehensive approach to asses-
sing the full range of psychometric (measurement properties) of
the questionnaire in order to conform to current international
standards.20–22 This required the simultaneous collection of a
wide array of patient-reported and clinician-reported outcome
measures in a large cohort of patients. A key strength of the
IBD-Control tool is that it has been developed primarily for
clinical application and to support patient-centred care. Hence,
our validation has not rested simply on showing correlations
with traditional disease measures across the patient population
but has considered the performance of summary scores at indi-
vidual level and for a specific clinical purpose.
We were particularly interested in generating a tool that
would reliably identify a patient in a ‘quiescent’ state, defined
stringently using a composite of criteria including physician
rating and treatment outcome. This has application to models of
care that seek to reduce the need for traditional face-to-face
consultation (eg, ‘virtual’ clinics). The instrument produces
scores relevant to the planning of day-to-day care, serving as a
potential trigger or triage tool to guide the necessity, timing and
nature of more formal clinical assessment. The inclusion of
items relating to concern about treatment or new symptoms
further distinguishes the IBD-Control from traditional QoL
tools. Hence, it is intended to provide information to support
patient-focused consultations and summary scores to support
traditional clinical assessment and decision-making.
Potential limitations of our approach to PROM development
was the adoption of rigid, prespecified design criteria that man-
dated the IBD-Control should contain only a small number of
‘general’ items with simple response categories to optimise
acceptability. This meant a pragmatic approach was taken to
item selection to favour broad, generically worded questions
covering core domains with active exclusion of items about indi-
vidual gastrointestinal symptoms. We did not undertake a
process of generating a very large number of items followed by
factor analysis and item reduction. We believe our approach was
justified by the wealth of existing published information identi-
fying key areas of concern for patients with IBD. We used quali-
tative data from patients to confirm that each item was relevant
to the concept of disease control. Nevertheless, there was a risk
that producing an instrument to this strict specification could
have resulted in suboptimal measurement properties. However,
the findings of our prospective evaluation suggest quite the
opposite—the IBD-Control questionnaire has very strong prop-
erties when compared with a wide array of external measures.
There is inevitable selection bias inherent in recruiting patients
willing to complete multiple questionnaires for a validation study.
However, our patient sample size was large and contained indivi-
duals with a broad spectrum of demographic and clinical attributes
that are similar to our local denominator IBD population.23
Although the proportion of cases with moderate-to-severe disease
was only 15–20%, the linear trends and consistent confidence
limits for IBD-Control scores observed across the disease spectrum
suggests sufficient cases in the study. By recruiting patients at the
time of ‘real-life’ clinical visits and asking for IBD-Control comple-
tion before other assessments we sought to reproduce the intended
application for the tool. Clearly, further validation in other settings
and in specific patient subgroups is desirable.
Current guidelines for IBD do not endorse the use of any spe-
cific PROM to guide the organisation or monitoring of care nor to
support patient-level decision-making. Hence, currently available
PROMs serve largely as research tools. This contrasts with some
other chronic diseases where the use of specific patient-centred
outcome measures has been incorporated into guidelines and care
pathways.1 Recently, quality improvement programmes for IBD in
a range of healthcare settings have highlighted the potential for
routine capture of PROMs to help drive better patient-centred ser-
vices.31 32 We suggest that the simplicity of the IBD-Control in
combination with its strong measurement properties and relevance
to both forms of IBD make it ideally suited to support such initia-
tives, in addition to having a potential role as an outcome measure
in pragmatic clinical trials. As an addition to routine clinical care,
the instrument offers the realistic possibility of capturing serial
PROM data with minimal user burden and its content is eminently
suited to adaptation to electronic capture via web-based systems,
portals or mobile devices.
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